Steroids

People with IBD sometimes are excluded from or uncertain about immune checkpoint inhibitor cancer trials because of concerns about triggering autoimmune flares. This trial explicitly studies safety and disease impact in...

Older adults with ulcerative colitis can rarely develop large-vessel giant cell arteritis as an extraintestinal complication.

Hydrocortisone injection is an FDA‑labelled corticosteroid option for short‑term control of severe flares or life‑threatening situations when oral therapy isn't feasible; the label explicitly names regional enteritis...

Patients and clinicians managing ulcerative colitis in India may have greater access to an effective oral treatment (tofacitinib) that can reduce steroid dependence and is available as lower-cost generics. This could...

A nationwide clinician survey identifies major variation in how acute severe ulcerative colitis is diagnosed, monitored, and when rescue therapy or surgery is used — differences that can affect patient outcomes and...

The trial explores a new way to boost regulatory T cells using low-dose IL-2, which could offer an alternative mechanism for people with Crohn's disease who haven't responded to existing therapies. It also links immune...

This DailyMed/FDA label update affects adults with moderately to severely active ulcerative colitis because it states approved use of tofacitinib extended‑release and highlights important safety warnings and recommended...

This label update details how injectable methylprednisolone can be used in acute/critical situations for inflammatory bowel diseases (regional enteritis/Crohn’s disease and ulcerative colitis), including dosing and...

This label is the official prescribing information for intravenous/intramuscular methylprednisolone (SOLU‑MEDROL). Corticosteroids are commonly used short‑term in IBD to treat moderate-to-severe flares when rapid...

VEOIBD often has a strong genetic component and different clinical needs than adult IBD; this study shows genetic findings and treatment challenges in a Middle East pediatric center, which may affect diagnosis and access...

A rare but serious colitis linked to ocrelizumab is described and managed successfully with ciclosporin in a steroid‑refractory case; this may be relevant to clinicians caring for patients on B‑cell–depleting therapy.

Guidelines recommend treating objective inflammation even when symptoms are mild because untreated disease can cause complications; the article describes escalation to risankizumab due to endoscopic inflammation, high...

This study suggests tofacitinib may work quickly as a rescue option for biologic‑naive patients with steroid‑refractory ASUC and that many achieved steroid‑free remission by 24 weeks — information that could matter when...

For patients and clinicians facing steroid- and infliximab-refractory acute severe ulcerative colitis, upadacitinib may be a third-line medical option that can produce rapid symptom and CRP improvement and allow some...

The FDA label for dexamethasone explicitly lists regional enteritis (Crohn's disease) and ulcerative colitis among its gastrointestinal indications, and provides dosing guidance and steroid-equivalent tables that are...

This study describes how IBD presents and early outcomes in children at a tertiary center, noting high rates of inflammation, nutritional problems, and early flares. Findings may help families and clinicians understand...

The study compares two oral steroid therapies used to induce remission in outpatient ulcerative colitis and reports similar short-term efficacy but different safety profiles — information that can inform treatment...

The FDA/DailyMed label defines approved uses and official dosing guidance for prednisone, a corticosteroid commonly used to treat moderate-to-severe inflammatory conditions including ulcerative colitis and regional...

People with ulcerative colitis who have had colectomy can rarely develop inflammation of the small intestine and high-output stomas that are hard to control.

GI perforation is a serious, potentially life-threatening complication that can occur in people with autoimmune diseases; this report highlights that perforation can happen during corticosteroid tapering and that careful...

This is the FDA DailyMed label for dexamethasone, which lists gastrointestinal uses including short-term use in ulcerative colitis and regional enteritis (Crohn's disease). Patients with IBD may be prescribed...

This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.

Mucosal healing is a treatment goal that aims to stop internal intestinal inflammation, not just symptoms. Achieving mucosal healing is linked with fewer hospitalizations, less need for surgery, and lower rates of...

Fatigue affects a large majority of pediatric IBD patients and is linked to worse quality of life even when disease is in remission, so it’s a common problem families and clinicians will likely encounter. Understanding...

The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...

Market reports can signal which drugs, companies, and biosimilars are becoming more available and may affect access and cost. Announcements about biosimilars could influence treatment affordability and prescribing...

This study suggests LVV can occur in people with IBD at younger ages and with distinct vascular findings, and it may arise even when gut disease is in remission. That matters for awareness, diagnosis, and coordination...

You can have active intestinal inflammation even without clear symptoms; early monitoring and tailored treatment aim to prevent complications and preserve quality of life.

Reducing long-term corticosteroid use matters because steroids have significant side effects when used repeatedly or chronically. The study suggests ileocaecal resection may lower steroid exposure for many patients, but...

New treatment studies and biosimilars could affect future options and access to care. The piece also points out growing pediatric Crohn’s care and supports available (like an infusion center).

If you have IBD or are at risk for colorectal disease, clinicians at the conference highlighted that these conditions are being seen more often and that treatment approaches have shifted toward personalized medicine and...

This article is a market research summary about the global Crohn’s disease treatment market — it describes sales forecasts, industry players, and market trends rather than new clinical findings or patient-focused...